9/23/2022

speaker
Norma
Conference Operator

Good day, and thank you for standing by. Welcome to NMED Pharmaceutical's fourth quarter fiscal 2022 financial results and business update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Colin Clancy, Vice President of Investor Relations. Please go ahead.

speaker
Colin Clancy
Vice President of Investor Relations

Thank you, Norma, and good day, ladies and gentlemen. My name is Colin Clancy, INMED's Vice President of Investor Relations. Welcome to INMED's fiscal year and 2022 financial results and business update conference call. Please note our speakers are joining today from remote locations, so we appreciate your patience if we encounter any unexpected technical challenges. Before we begin, we would like to go over our disclosure statements, followed by a progress report on our Pharmaceutical Drug Development Program, led by our President and CEO, Eric Adams, together with an update on our health and wellness commercial activities, which will be provided by Michael Woodenberg, our Chief Operating Officer. Ms. Brenda Edwards, our Interim Chief Financial Officer, will then review the financial results of operations. Following that, we will be available for question and answer sessions. Also joining us today to address your questions is Dr. Eric Su, Senior Vice President of Preclinical Research and Development. Please be advised that certain statements in the following conference call, including expectations for in-meds business operations, clinical development, key personnel, contractual arrangements, regulatory approvals, revenue opportunities, financing, and cash runaway, all constitute forward-looking statements. Such statements are not historical facts, but rather predictions about the future, which inherently involve assumptions, risks, and uncertainties. Actual results may differ materially from those contained in the forward-looking statements. A description of these risks can be found in our latest disclosure document. INMED does not undertake any obligation to update any forward-looking statements made during this call. I would now like to turn over to INMED's President and CEO, Eric Adams.

speaker
Eric Adams
President and Chief Executive Officer

Thanks, Colin, and thank you to everyone for joining us today. Since our last earnings call, there have been several significant and eventful changes, both in relation to operations and on the corporate level. We have seen several macro socioeconomic issues in 2022, including increasing recessionary pressures, the largest inflation growth in decades, the ongoing war in Ukraine, as well as the slow emergence from the COVID pandemic, all of which have had a direct and considerable impact on many businesses, as well as the global stock market. Specifically, 2022 has seen the worst stock market performance for biotech companies in decades, causing significant challenges in the capital markets, especially for small-cap pharmaceutical R&D companies that rely on investment to advance clinical development and other programs. InMed has not been immune to these overarching influences. That said, InMed has managed to navigate these headwinds and gain positive momentum across our operations, and continue to advance our preclinical and clinical programs, especially our phase two clinical trial in the treatment of EB. On a corporate level, we've had several capital market related events, including two recent financings to bolster our balance sheet to ensure we have sufficient capital to execute on our programs. Let me start with discussing our pharmaceutical drug development programs, beginning with INM 755, or epidermolysis bullosa, or EB. For those of you who are new to the study, INMED is evaluating the safety of INM755 cannabinol cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period in individuals diagnosed with EB. The study is designed to enroll up to 20 patients and marks the first time that cannabinol, also known as CBN, has advanced into a phase two clinical trial to be investigated as a therapeutic option to treat the specific disease. IMET's phase two clinical trial now has nine clinical trial sites fully activated to screen and enroll patients. Two more sites are expected to be fully activated soon. The clinical trial is taking place in seven countries, including Austria, Germany, Greece, France, Italy, Israel, and Spain. This phase two clinical trial continues to progress. Since our last call, patient screening and enrollment continued and nine patients have been enrolled and completed the study. Following a period of downtime during the summer months, patient screening and enrollment have now recommenced. In the fourth fiscal quarter, based on safety data of the first five adult patients who completed treatment, an independent data monitoring committee agreed it was safe to enroll adolescent patients defined as persons aged 12 to 17 into our trial. The first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece during the summer. The company anticipates that the inclusion of adolescents will have a positive impact on the enrollment rate for the remainder of the clinical trial. As a result, We expect enrollment into the trial to complete during the calendar year 2022 and a data readout expected in the first quarter of calendar 2023. Now turning to INM 088. The company continues to advance its pre-clinical research on CBN as treatment for glaucoma. In the fourth fiscal quarter, the company completed pre-investigational new drug application discussions with the U.S. Food and Drug Administration regarding manufacturing, preclinical studies, and early clinical development plans for INM088. We gained alignment on the design of the initial Phase I-II clinical trial to gather preliminary data on the safety and efficacy of INM088 treatment in glaucoma. We continue to work towards completing the necessary preclinical studies in anticipation of an investigational new drug application filing in the first half of calendar year 2024, seeking regulatory permission to initiate a human clinical trial. I'd now like to speak to our work on neurodegenerative disease. As a pharma company, it is imperative that we continue to add to our pipelines. Therefore, I think it's important to point out that our pharmaceutical drug development program also includes exploring other rare cannabinoids and cannabinoid analogs for their therapeutic effects. Last November, we filed an international patent application seeking commercial exclusivity for the potential treatment of important neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and others by demonstrating neural protection and promotion of neurite growth in a population of affected neuronal cells using a different rare cannabinoid. Since then, screening for this indication has yielded some meaningful analog candidates, and we will continue with our plans to find an appropriate compound for continuing preclinical development. Let's move over to our analog strategy. Advancing the research and development of cannabinoid analogs remains a high priority for the company. In April, we announced the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses, and methods of manufacturing. Such patent protection on the underlying molecule itself is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D. At the same time, we initiated an important research collaboration with Dr. Mauro Maccarone at the University of L'Aquila in Italy. Dr. Macaroni is an international expert in cannabinoid research and a founding member of the European Cannabinoid Research Alliance. He is investigating the potential utility of a group of cannabinoid analogs in the treatment of ocular disease. Considering the enhanced commercial protection afforded with a proprietary patented analog, this is an area where we intend to place additional focus in the coming years. Now I'd like to hand over to our COO, Michael Wudenberg, who will provide an update on BayMedica's commercial activities. Mike? Mike, are you on mute?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-